Signaling via TGFβ receptors – possible targets in tumor treatment


Wednesday, November 20, 2019, at 17:00 in auditorium F

Lecture given by Professor Carl-Henrik HELDIN

Chair of the Board of the Nobel Foundation & Professor in Molecular Cell Biology, University of Uppsala, Sweden


The lecture will be followed by a reception at the de Duve Institute.


Professor Carl-Henrik Heldin is a world authority in molecular biology and cancer research. A Professor of Molecular Cell Biology at the University of Uppsala, he was the Director of the Uppsala branch of the Ludwig Institute for Cancer Research and also served as Vice-President of the European Research Council. In 2013, he was elected Chairman of the Nobel Foundation's Board of Directors.

His research focuses on the mechanisms of signal transduction by growth regulatory factors, as well as their normal function and role in disease. In particular, platelet-derived growth factor (PDGF), a major mitogen for connective tissue cells, and transforming growth factor β (TGFβ), which inhibits the growth of most cell types, are studied. The ultimate goal is to explore the possible clinical utility of signal transduction antagonists for the treatment of malignant diseases.

A contributor to over 600 papers with close to 70,000 citations, Carl-Henrik Heldin has received many scientific awards and academic honors. He chairs or has chaired a large number of scientific advisory boards, including the European Molecular Biology Laboratory and the German Cancer Center in Heidelberg, and the Center for Molecular Medicine in Vienna. A member of the Royal Swedish Academy of Sciences, he was elected to the American Academy of Arts and Sciences in 2016.


Please register here
before November 15

*** For security reasons, registration is mandatory and participants are invited to carry identification ***



Auditoire F
Avenue E. Mounier 51
1200 Bruxelles

Metro Alma



Nathalie Krack